ML-18 - Names and Identifiers
ML-18 - Physico-chemical Properties
Molecular Formula | C32H35N5O5
|
Molar Mass | 569.66 |
Density | 1.291±0.06 g/cm3(Predicted) |
Boling Point | 821.8±65.0 °C(Predicted) |
Solubility | DMSO: ≥100 mg/mL |
pKa | 11.99±0.46(Predicted) |
Storage Condition | 2-8°C |
In vitro study | ML-18 inhibits specific 125 I-BA1 (DTyr-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH2)BB6-14 binding to NCI-H1299 lung cancer cells stably transfected with BRS-3 with IC 50 values of 4.8 μM. ML-18 binds with lower affinity to the GRPR and NMBR with IC 50 values of 16 and more than 100 μM, respectively. ML-18 at 16 μM inhibits the ability of 10 nM BA1 to elevate cytosolic Ca 2+ in a reversible manner using lung cancer cells loaded with FURA2-AM. ML-18 at 16 μM inhibits the ability of 100 nM BA1 to cause tyrosine phosphorylation of the EGFR and ERK in lung cancer cells. It inhibits the proliferation of lung cancer cells. |
ML-18 - Preparation solution concentration reference
| 1mg | 5mg | 10mg |
---|
1 mM | 1.755 ml | 8.777 ml | 17.555 ml |
5 mM | 0.351 ml | 1.755 ml | 3.511 ml |
10 mM | 0.176 ml | 0.878 ml | 1.755 ml |
5 mM | 0.035 ml | 0.176 ml | 0.351 ml |
Last Update:2024-01-02 23:10:35
ML-18 - Reference Information
biological activity | ML-18 is a non-peptide bombesin receptor subtype -3 (BRS-3) antagonist that inhibits the growth of lung cancer. |
Target | IC50: 4.8 μm (BRS-3) |
Last Update:2024-04-09 19:05:17